Hookipa raises $60M to fund immunotherapy R&D; Roche bags Ionis option for $45M; Regeneron fights back against Novartis' Eylea rival
→ Hookipa Biotech has raised $60 million (€50 million) in an oversubscribed Series C round to help push its lead program, a vaccine for infections …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
